Biotech Specialty Pharma

Favrille, Inc.

10421 Pacific Center Court, Suite 150
San Diego, CA 92121 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Immunotherapies for the treatment of cancer and immune system diseases.

Management John P. Longenecker, Ph.D., President and CEO; Daniel P. Gold, Ph.D., Founder & Chief Scientific Officer; Tamara A. Seymour, Chief Financial Officer and Vice President of Finance and Administration; David Guy, Chief Commercial Officer; Richard Murawski, Senior Vice-President of Operations; John F. Bender, Pharm.D., Vice-President of Clinical Research; Alice Wei, Vice-President, Regulatory Affairs and Quality

Click here for Financial Data
Keywords: immunotherapy, cancer, immune system, lymphoma


Updated: Aug. 08, 2007


Favrille, Inc. is a clinical development-stage company developing patient-specific active immunotherapies for lymphoma and disease of the immune system. ......view more

Revenue / Funding

The Company has been funded through sales of preferred stock totaling $77 million. ...view more


Favrille has completed enrollment in two Phase II clinical trials and entered a pivotal Phase III clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma in July of 2004....view more